Abstract
For patients with acute myeloid leukemia, DNA sequencing before stem cell transplant can predict the chances of relapse, research shows. Scientists found that NPM1 alterations and/or FLT3 internal tandem duplications that persist after treatment and prior to a stem cell transplant were better predictors of relapse than flow cytometry.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
